Treatment with Sifalimumab (anti-IFNα mAb) and Anifrolumab (anti-IFNAR mAb) showed an improvement of skin disease activity scores in SLE patients presenting with cutaneous disease in Phase II clinical trials further supporting the contribution of IFN-I to the pathogenesis of CLE (10, 11). The gene discussed is IFNA1; the disease is systemic lupus erythematosus.